← Back to Search

Procedure

Treatment for Thoracic Diseases (EXTEND Trial)

N/A
Recruiting
Led By Martin Czerny
Research Sponsored by Vascutek Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the primary effectiveness endpoint will be measured at one-year after the index procedure.
Awards & highlights

Summary

The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at each participating site. Participant involvement in the study will last for a total of 10 years from the point at which the Thoraflex Hybrid device is placed.

Eligible Conditions
  • Thoracic Diseases
  • Dissecting Aneurysm
  • Aortic Aneurysm
  • Aortic Dissection
  • Thoracic Aortic Aneurysm
  • Thoracic Aortic Dissection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the primary effectiveness endpoint will be measured at one-year after the index procedure.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the primary effectiveness endpoint will be measured at one-year after the index procedure. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Effectiveness Endpoint: Treatment Success
Primary Safety Endpoint is a composite of the following
Secondary outcome measures
Secondary Safety Endpoints, Absence of the following
Secondary effectiveness endpoints will be reported

Find a Location

Who is running the clinical trial?

Vascutek Ltd.Lead Sponsor
16 Previous Clinical Trials
5,545 Total Patients Enrolled
Bolton MedicalIndustry Sponsor
16 Previous Clinical Trials
2,651 Total Patients Enrolled
Martin CzernyPrincipal InvestigatorUniversity of Freiburg
~133 spots leftby Dec 2035
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top